MESO · Mesoblast Limited

The thesis

Mesoblast's case is that sales of its approved cell therapy Ryoncil can fund the pipeline without another equity raise. The September 2026 quarter weakened that case: Ryoncil net revenue was about US$28 million, down roughly 22% from US$36 million in the June quarter (business-news-today.com, reporting the company's 16 October 2026 announcement). The shares closed at $13.18 on 27 October 2026, 37.1% below the 52-week high of $20.96.

The sales figure was up 44% from about US$19 million a year earlier, so the product is growing year on year. It is not growing quarter on quarter. The December 2026 quarter decides whether the June figure was a peak or a step on the way up.

The narrative is maturing: the fiscal 2026 results of 27 August 2026 are well known, and the first sequential dip arrived on 16 October 2026. The rating stays low because the one operating datapoint since the previous note came in under the level that note named as a risk.

Bullish and bearish views on Mesoblast Limited

The bull case on Mesoblast Limited (MESO), in brief: Ryoncil is growing year on year. The bear case: Sales fell from the prior quarter.

Bull case

• Ryoncil is growing year on year. Net revenue of about US$28 million in the September 2026 quarter compares with about US$19 million a year earlier, a 44% gain (Motley Fool Australia, 16 October 2026). Fiscal 2026 Ryoncil net revenue was US$115.2 million (results release, 27 August 2026).
• Cash burn collapsed. Net operating cash spend was about US$2.3 million in the September quarter against US$14.9 million a year earlier (Motley Fool Australia, 16 October 2026). Cash was about US$99 million at 30 September 2026, from US$103 million at 30 June 2026.
• Debt service is light near term. The US$125 million five-year facility carries a fixed 8% rate and is interest-only through December 2030, according to business-news-today.com (16 October 2026).
• Manufacturing quality control was cleared. The FDA approved a new T-cell proliferation inhibition bioassay for all new commercial Ryoncil lots, used alongside existing potency assays (company announcement, 24 September 2026).
• A sell-side analyst remains constructive. Piper Sandler reiterated Overweight and raised its target to $39 from $35 on 27 August 2026, per Benzinga. That target is far above the $13.18 close.

Bear case

• Sales fell from the prior quarter. September-quarter net revenue of about US$28 million sits roughly 22% under the US$36 million of June (business-news-today.com, 16 October 2026). Management had guided to double-digit Ryoncil growth over the coming 12 months on the 26 August 2026 call.
• The company still has no net cash. Cash of about US$99 million sits against a fully drawn US$125 million facility secured on Ryoncil royalties. Fiscal 2026 net loss was US$57.5 million (results release, 27 August 2026).
• One product carries the revenue. Nearly all sales come from one pediatric orphan indication, so quarter-to-quarter swings in gross-to-net and payer mix move the whole case.
• The key trial date is imprecise. The written release of 27 August 2026 guides the chronic low back pain Phase 3 readout to mid-2027. CEO Silviu Itescu said second half of 2027 on the call a day earlier. No scheduled binary event falls in the next six months.
• Price momentum is weak. The close of $13.18 on 27 October 2026 is 37.1% below the 52-week high, with a three-month change of -9.4%.

Price setup

The shares have fallen through each of those levels and have not recovered the $15 area that held from July to August.

The 14-day relative strength index was 43.4 on 27 October 2026, up from 31.0 on 14 October 2026. That is a neutral reading: selling pressure has eased without a rebound in price. A close below $13.00 would extend the decline, and a close back above $15.13 would reverse the slide since mid-September.

Crowding evidence is thin. The earnings-type datapoint has passed, and none of the coverage found of the 16 October 2026 report mentions a share issue. Mesoblast is a foreign private issuer, so insiders file ASX notices rather than SEC Form 4, and US insider screens show nothing by construction.

Catalysts, next 30 days

• ~2027-01 (est.): December 2026 quarter activities and cash-flow report. It shows whether Ryoncil sales recover above US$36 million or keep falling.
• Mid-to-second-half 2027: Chronic low back pain Phase 3 readout, the binary pipeline event.

Elapsed catalysts

• Q4 2026, timing not announced: Company discussion with the FDA on a modular filing for gastrointestinal bleeding in patients with left ventricular assist devices. Management said on 26 August 2026 it would hold the talks "next quarter". A defined path widens the pipeline beyond the low back pain trial. (passed 72d ago)
• No dated company event is confirmed for the next 30 days. The September-quarter sales and cash figures are already out (16 October 2026). (passed 21d ago)

What would change the view

The case breaks if Ryoncil net revenue falls again in the December 2026 quarter, or if the company announces a placement, public offering or at-the-market program. Either would show the product cannot fund the pipeline alone. A daily close below $13.00 would also end the case on price, extending the slide from the $13.79 close of 14 October 2026.

The case improves if December-quarter net revenue exceeds the US$36 million of June 2026 while operating cash spend stays near the September level. A written FDA path for the left ventricular assist device indication would add pipeline value. Neither is in evidence yet.

What it trades with

Mesoblast trades as a single-product cell-therapy company with a binary Phase 3 event ahead, so its moves follow its own sales prints, financing news and FDA announcements more than the broad market. Nasdaq-traded American depositary shares (MESO) often move with the prior Australian session in the ordinary shares (MSB). Motley Fool Australia reported on 16 October 2026 that the ordinary shares were down 29% over 12 months while the S&P/ASX 200 fell 2%.